Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for Chronic or Refractory ITP
NCT06352281Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of LV20.19 CAR-T in immune thrombocytopenia (ITP). Started Feb 2024; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06352281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352281.